1. Home
  2. GEVO vs PRTC Comparison

GEVO vs PRTC Comparison

Compare GEVO & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$2.00

Market Cap

468.8M

Sector

Industrials

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.87

Market Cap

400.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
PRTC
Founded
2005
2015
Country
United States
United States
Employees
151
90
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
468.8M
400.2M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
GEVO
PRTC
Price
$2.00
$17.87
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$6.42
N/A
AVG Volume (30 Days)
4.4M
3.2K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
58.82
N/A
EPS
N/A
N/A
Revenue
$711,000.00
N/A
Revenue This Year
$19.44
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$14.50
52 Week High
$2.97
$19.92

Technical Indicators

Market Signals
Indicator
GEVO
PRTC
Relative Strength Index (RSI) 41.32 66.42
Support Level $1.94 $16.60
Resistance Level $2.19 $18.12
Average True Range (ATR) 0.20 0.40
MACD -0.07 0.34
Stochastic Oscillator 10.36 87.31

Price Performance

Historical Comparison
GEVO
PRTC

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: